Mater Private Network chosen as the first hospital in Ireland to implement Abbott’s new Assert-IQTM Insertable Cardiac Monitor

Mater Private Network has been chosen for a limited market release of Abbott’s new Assert-IQ^TM Insertable Cardiac Monitor (ICM), making it the first hospital in Ireland to offer this new technology to patients. Prof. Mark Dayer, Head of Heart Failure at Mater Private Network in Dublin, carried out the first procedure today. Subsequently, the device will be rolled out across our sites in Dublin and Cork, improving the detection and treatment of arrhythmias in patients across our network.  With the device’s improved insights, clinicians can now detect premature ventricular contractions (PVCs); record if a patient became unstable or felt dizzy during an episode; track elevated heart rate with and without physical activity; and assess trends over time. When combined, the device offers a more holistic view of the patients’ condition and allows for a more accurate detection of arrhythmias.  

Speaking about this development, Prof. Dayer said “As the first hospital in Ireland to offer this technology, Mater Private Network remains at the forefront of innovation in the field of cardiac care and treatment of arrhythmias. The Assert-IQ^TM ICM, by providing us with an ability to continuously monitor the heart rhythm of our patients, allows for earlier detection of many cardiac events. This real-time data empowers our medical team to intervene promptly, improving patient outcomes and possibly reducing the risk of complications. By making this device available, we’re ensuring that patients receive the highest standard of care, with enhanced diagnostic capabilities and personalised treatment plans”.